Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study being conducted at multiple centers in the United States and Germany.
Patients having non-small cell lung cancer that has spread to other parts of the body (i.e.,
metastatic) or is locally advanced (i.e., Stage IIIB with malignant pleural effusion) are
eligible to participate. Patients must have disease that has been treated with at least 1
prior treatment for metastatic disease (prior adjuvant treatment for localized disease does
not count as prior treatment for metastatic disease). The purpose of the study is to test
whether the angiogenesis inhibitor AG-013736 is an effective treatment for advanced non-small
cell lung cancer as shown by the number of patients in the study who experience significant
and durable tumor shrinkage